Market Overview

UPDATE: BMO Capital Markets Initiates Abbott Laboratories at Outperform on Growth, Margin Expansion

Related ABT
Amid Headline Risk, Barclays Says St. Jude's Pipeline Underestimated
Fed Speakers And Beige Book, Bank Earnings, Rising Crude Take Center Stage
60% Return From Reynolds' Smoking Hot Opportunity (Seeking Alpha)

BMO Capital Markets initiated coverage on Abbott Laboratories (NYSE: ABT) with an Outperform rating and a $36 price target.

BMO Capital Markets noted, "The new Abbott is expected to deliver 2012E sales of $21.5B (flat; up 4% ex-FX) from four distinct businesses: Nutritionals (30% of sales); Medical Products (26%); Established Pharmaceuticals (24%); and Diagnostics (20%). With leading market share positions and an extensive geographic footprint, particularly in the emerging markets (about 40% of revenue), we expect the company to benefit from a focused management team and dedicated resources, to drive mid- to high-single-digit revenue growth, expand operating margins, and deliver double-digit EPS."

Abbott Laboratories closed at $31.40 on Monday.

Latest Ratings for ABT

Sep 2016JefferiesMaintainsBuy
Aug 2016JefferiesMaintainsBuy
Jul 2016JefferiesMaintainsBuy

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: BMO Capital MarketsAnalyst Color Initiation Intraday Update Analyst Ratings


Related Articles (ABT)

View Comments and Join the Discussion!